Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients

Biol Psychiatry. 1993 Feb 15;33(4):227-35. doi: 10.1016/0006-3223(93)90288-o.

Abstract

The relationship between central D2-dopamine receptor occupancy and antipsychotic drug effects was examined in a double-blind study. Raclopride was the compound used to induce a selective occupancy of the D2-dopamine receptors. In addition, 11C-labeled raclopride was the radioligand used to measure occupancy by positron emission tomography (PET). Seventeen schizophrenic patients were randomly assigned to one of three parallel groups treated for 4 weeks with daily doses of 2, 6, or 12 mg of raclopride. D2-receptor occupancy was determined by PET at steady-state conditions in 13 patients who completed the study. A statistically significant relationship was demonstrated between antipsychotic effect and degree of D2-receptor occupancy (p < 0.05). Patients with extrapyramidal side effects had significantly higher D2-receptor occupancy than those without (p = 0.02). The finding of a relationship between selective occupancy of the D2-dopamine receptors and clinical effects in schizophrenic patients principally provides new support for the dopamine hypothesis of antipsychotic drug action.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / blood
  • Antipsychotic Agents / therapeutic use*
  • Brain / diagnostic imaging*
  • Dopamine D2 Receptor Antagonists
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Psychiatric Status Rating Scales
  • Raclopride
  • Receptors, Dopamine D2 / drug effects*
  • Salicylamides / adverse effects
  • Salicylamides / blood
  • Salicylamides / therapeutic use*
  • Schizophrenia / diagnostic imaging*
  • Schizophrenia / drug therapy
  • Schizophrenic Psychology
  • Tomography, Emission-Computed

Substances

  • Antipsychotic Agents
  • Dopamine D2 Receptor Antagonists
  • Receptors, Dopamine D2
  • Salicylamides
  • Raclopride